Rivoceranib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Rivoceranib
Accession Number
DB14765
Type
Small Molecule
Groups
Investigational
Description

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Structure
Thumb
Synonyms
  • APATINIB
Categories
UNII
5S371K6132
CAS number
811803-05-1
Weight
Average: 397.482
Monoisotopic: 397.190260381
Chemical Formula
C24H23N5O
InChI Key
WPEWQEMJFLWMLV-UHFFFAOYSA-N
InChI
InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
IUPAC Name
N-[4-(1-cyanocyclopentyl)phenyl]-2-{[(pyridin-4-yl)methyl]amino}pyridine-3-carboxamide
SMILES
O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rivoceranib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rivoceranib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rivoceranib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Rivoceranib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9490441
ChEMBL
CHEMBL3186534
Wikipedia
Apatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentSarcomas1
1Active Not RecruitingTreatmentMalignancies1
1Active Not RecruitingTreatmentOvarian Cancer / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentNeoplasms2
1Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
1Not Yet RecruitingTreatmentCancer, Advanced1
1Not Yet RecruitingTreatmentMetastatic Cancers / Neoplasms Malignant / Tumors, Solid1
1RecruitingOtherCancer, Advanced1
1RecruitingTreatmentCytochrome P450 Interaction1
1RecruitingTreatmentGastric Adenocarcinoma1
1RecruitingTreatmentMalignant Neoplasm of Stomach1
1RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
1RecruitingTreatmentNasopharyngeal Carcinoma1
1RecruitingTreatmentRecurrent and Metastatic Gastric Cancer1
1RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1Unknown StatusTreatmentTumors1
1, 2Active Not RecruitingTreatmentAdvanced Malignancies / Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma / MSI-H or dMMR Solid Tumors / Transitional Cell Carcinoma1
1, 2CompletedTreatmentCancer Patients With Solid Tumors1
1, 2Not Yet RecruitingTreatmentAdvanced Solid Tumors / Excluding T Cell Lymphoma1
1, 2Not Yet RecruitingTreatmentChronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms / Respiratory Tract Diseases / Thoracic Neoplasms1
1, 2Not Yet RecruitingTreatmentGastric Carcinoma1
1, 2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
1, 2Not Yet RecruitingTreatmentLung Cancers1
1, 2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
1, 2RecruitingTreatmentAdvanced Gastric Cancer1
1, 2RecruitingTreatmentApatinib / Combination Chemotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2RecruitingTreatmentCRC1
1, 2RecruitingTreatmentHead and Neck Carcinoma1
1, 2RecruitingTreatmentHepatocellular,Carcinoma1
1, 2RecruitingTreatmentHepatocellular,Carcinoma / Malignant Neoplasm of Stomach1
1, 2RecruitingTreatmentHepatocellular,Carcinoma / Transplantation, Liver1
1, 2RecruitingTreatmentHigh-Grade Gliomas1
1, 2RecruitingTreatmentRecurrent Colorectal Cancer1
1, 2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung1
2Active Not RecruitingTreatmentApatinib / Metastasis / Recurrences / Squamous Cell Carcinoma of Esophagus1
2Active Not RecruitingTreatmentBreast Cancer3
2Active Not RecruitingTreatmentCarcinoma, Adenoid Cystic1
2Active Not RecruitingTreatmentClinical Benefit Rate / Overall Survival / Progression-free Survival / Therapeutic Agent Toxicity1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach Stage II / Malignant Neoplasm of Stomach Stage IV1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
2Active Not RecruitingTreatmentNeoplasms, Esophageal1
2Active Not RecruitingTreatmentOvarian Cancer1
2Active Not RecruitingTreatmentStomach Neoplasms1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentEfficacy and Safety1
2CompletedTreatmentIntrahepatic Cholangiocarcinoma / Second-line Treatment1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentMetastatic Breast Cancer1
2CompletedTreatmentNeoplasms, Breast1
2Not Yet RecruitingTreatmentACC1
2Not Yet RecruitingTreatmentAdvanced Esophagus Cancer1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
2Not Yet RecruitingTreatmentAdvanced Metastatic Gastric Cancer1
2Not Yet RecruitingTreatmentAdvanced Non-squamous Non-small-cell Lung Cancer1
2Not Yet RecruitingTreatmentAdvanced Pancreatic Cancer1
2Not Yet RecruitingTreatmentAngiogenesis / Cancer treatment / Colorectal Cancers1
2Not Yet RecruitingTreatmentBiliary Carcinoma1
2Not Yet RecruitingTreatmentBreast Cancer1
2Not Yet RecruitingTreatmentCancer, Advanced / Gastric Adenocarcinoma1
2Not Yet RecruitingTreatmentCervical Cancers1
2Not Yet RecruitingTreatmentChemotherapy Effect / KRAS Gene Mutation / NSCLC Stage IV / PD-1 Antibody1
2Not Yet RecruitingTreatmentChronic Lung Diseases / Neoplasms / Non-Small-Cell Lung / Respiratory Tract Diseases / Thoracic Neoplasms1
2Not Yet RecruitingTreatmentColorectal Cancers / Neoadjuvant Therapy1
2Not Yet RecruitingTreatmentEsophageal Cancers1
2Not Yet RecruitingTreatmentGastric Adenocarcinoma1
2Not Yet RecruitingTreatmentGastric Cancer With Positive Exfoliative Cancer Cells1
2Not Yet RecruitingTreatmentGliomas1
2Not Yet RecruitingTreatmentHepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma4
2Not Yet RecruitingTreatmentCancer treatment / Hypopharyngeal Carcinoma / Immunotherapy1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2Not Yet RecruitingTreatmentLung Cancers2
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach3
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
2Not Yet RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2Not Yet RecruitingTreatmentNK/T-cell Lymphoma1
2Not Yet RecruitingTreatmentNeoplasms, Colorectal1
2Not Yet RecruitingTreatmentNeoplasms, Esophageal1
2Not Yet RecruitingTreatmentOvarian Cancer3
2Not Yet RecruitingTreatmentPancreatic Cancer Metastatic1
2Not Yet RecruitingTreatmentRecurrent, Platinum-resistant Ovarian Cancer1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma, Adult, Stage II1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2Not Yet RecruitingTreatmentTumors Metastatic to Brain1
2RecruitingPreventionExtensive-Stage Small Cell Lung Cancer / Lung Cancers1
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction1
2RecruitingTreatmentAdvanced Biliary Tract Carcinoma / Advanced Primary Liver Cancer1
2RecruitingTreatmentAdvanced Esophageal Squamous Carcinoma1
2RecruitingTreatmentAdvanced Melanoma1
2RecruitingTreatmentAdvanced Non Small Cell Lung Cancer / Advanced Non Squamous Non Small Cell Lung Cancer1
2RecruitingTreatmentAdvanced Triple-Negative Breast Cancer1
2RecruitingTreatmentAngiogenesis Inhibitors,Ovarian Neoplasms1
2RecruitingTreatmentApatinib in Maintenance Treatment1
2RecruitingTreatmentApatinib / Biomarkers / Malignant Neoplasm of Stomach1
2RecruitingTreatmentApatinib / Cancer, Advanced / Mucosal Melanoma / SHR-12101
2RecruitingTreatmentApatinib / Esophageal Cancers / Metastatic Esophageal Cancer1
2RecruitingTreatmentApatinib / Lung Cancer Metastatic / Sarcoma, Osteogenic1
2RecruitingTreatmentApatinib / Malignant Ascites1
2RecruitingTreatmentApatinib / Metastasis / Thyroid1
2RecruitingTreatmentApatinib / Cancer treatment / Persistent Advanced Cervical Carcinoma / Recurrent Cervical Carcinoma / Targeted Therapy / Vascular Endothelial Growth Factor 2 Inhibitor1
2RecruitingTreatmentBiliary Tract Cancer1
2RecruitingTreatmentBiliary Tract Neoplasms1
2RecruitingTreatmentBreast Cancer2
2RecruitingTreatmentC-staged Hepatocellular Carcinoma in BCLC Classification1
2RecruitingTreatmentCancer, Advanced / Overall Survival / Progression-free Survival / Soft Tissue Sarcoma Adult / Therapeutic Agent Toxicity1
2RecruitingTreatmentCarcinoma of Gallbladder1
2RecruitingTreatmentCarcinoma, Adenoid Cystic1
2RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Malignant Neoplasm of Stomach1
2RecruitingTreatmentChemotherapeutic Toxicity / Ovarian Cancer1
2RecruitingTreatmentColorectal Cancers3
2RecruitingTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentGastric Adenocarcinoma1
2RecruitingTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
2RecruitingTreatmentGestational Trophoblastic Disease1
2RecruitingTreatmentGliomas1
2RecruitingTreatmentHCC1
2RecruitingTreatmentHER-2 Negatived Gastric Cancer1
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentHepatocellular,Carcinoma3
2RecruitingTreatmentIntrahepatic Cholangiocarcinoma1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)8
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)5
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentLung, Carcinoma1
2RecruitingTreatmentMalignant Melanoma1
2RecruitingTreatmentMalignant Neoplasm of Stomach4
2RecruitingTreatmentMetastatic Breast Cancer1
2RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)2
2RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
2RecruitingTreatmentMetastatic Gastric Cancers1
2RecruitingTreatmentNasopharyngeal Neoplasms2
2RecruitingTreatmentNeoplasms, Colorectal1
2RecruitingTreatmentNeoplasms, Head and Neck2
2RecruitingTreatmentNeoplasms, Pancreatic1
2RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2RecruitingTreatmentOsteosarcoma, Advanced1
2RecruitingTreatmentOvarian Cancer1
2RecruitingTreatmentPancreatic Cancer Metastatic1
2RecruitingTreatmentRadiation Injuries1
2RecruitingTreatmentRecurrent Cervical Carcinoma / Recurrent, IV-B Cervical cancer1
2RecruitingTreatmentRefractory Cancer1
2RecruitingTreatmentRefractory or Metastatic Esophageal Squamous Cell Carcinoma1
2RecruitingTreatmentSafety and Effectiveness of Apatinib Combined With SOX Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer1
2RecruitingTreatmentSarcomas3
2RecruitingTreatmentSoft Tissue Sarcoma (STS)2
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus3
2RecruitingTreatmentSystematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer1
2RecruitingTreatmentThyroid Cancers2
2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTwo Different Treatment Methods1
2, 3CompletedTreatmentGastric Carcinoma1
2, 3CompletedTreatmentMetastasis / Sarcoma, Osteogenic1
2, 3Enrolling by InvitationTreatmentBreast Cancer1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma / Pulmonary Metastasis1
2, 3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma1
2, 3RecruitingScreeningEsophageal Gastric Cardia Type Metaplasia / Esophagus Cancer, Stage III / Esophagus Cancer, Stage IV1
2, 3RecruitingScreeningLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentGastric Carcinoma1
2, 3RecruitingTreatmentGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma1
2, 3RecruitingTreatmentMalignant Neoplasm of Stomach2
3Active Not RecruitingTreatmentGastric Adenocarcinoma / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentAdvanced or Metastatic Gastric Cancer1
3Enrolling by InvitationTreatmentApatinib1
3Not Yet RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction1
3Not Yet RecruitingTreatmentApatinib / Capecitabine / Digestive System Neoplasms / Molecular Mechanisms of Pharmacological Action / Neoplasms / Neoplasms, Gastrointestinal / Stomach Diseases / Stomach Neoplasms1
3Not Yet RecruitingTreatmentGastric Carcinoma1
3Not Yet RecruitingTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
3Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
3RecruitingTreatmentApatinib / EGFR-TKI / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
3RecruitingTreatmentEGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors1
3RecruitingTreatmentLocally Advanced or Metastatic and Unresectable HCC1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentMalignant Neoplasm of Stomach2
3RecruitingTreatmentOvarian Cancer1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4CompletedTreatmentBreast Cancer / Cervical Cancers / Esophageal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignancies / Malignant Neoplasm of Stomach / Ovarian Cancer1
4CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Relapsed /Refractory Diffuse Large B Cell Lymphoma / Relapsed and Refractory1
4Not Yet RecruitingTreatmentAdvanced Non-squamous Non-small-cell Lung Cancer1
4Not Yet RecruitingTreatmentLung Squamous Cell Carcinoma1
4RecruitingOtherStage IV Cancer1
4RecruitingTreatmentMalignant Neoplasm of Stomach1
4RecruitingTreatmentNewly Diagnosed Peripheral T-cell Lymphoma1
Not AvailableCompletedTreatmentEfficacy / Therapeutic Agent Toxicity1
Not AvailableCompletedTreatmentQuality of Life1
Not AvailableNot Yet RecruitingNot AvailableNonsquamous Nonsmall Cell Neoplasm of Lung1
Not AvailableNot Yet RecruitingNot AvailableProgression-free Survival;Progression-free Survival;Disease Control Rate; Safety1
Not AvailableNot Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentMalignant Neoplasm of Stomach1
Not AvailableRecruitingNot AvailableGlioblastomas1
Not AvailableRecruitingNot AvailableNon-Squamous Non-Small Cell Lung Cancer1
Not AvailableRecruitingNot AvailableRecurrent Gliomas1
Not AvailableRecruitingTreatmentApatinib / Chemotherapy, Adjuvant / Colorectal Cancers / General Surgery / Outcome, Fatal1
Not AvailableRecruitingTreatmentCervical Cancers1
Not AvailableRecruitingTreatmentEsophageal Cancers1
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma2
Not AvailableRecruitingTreatmentPeritoneal Metastases From Gastric Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.14ALOGPS
logP4.29ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.23ChemAxon
pKa (Strongest Basic)5.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.7 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.16 m3·mol-1ChemAxon
Polarizability43.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:25 / Updated on November 02, 2019 03:26